{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:27:45Z","timestamp":1773016065721,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs) are at increased risk of venous thromboembolism (VTE). Standard prophylaxis typically involves aspirin or low-molecular-weight heparin (LMWH), guided by risk assessment tools such as SAVED and IMPEDE-VTE. However, these models have practical limitations, and real-world evidence supporting novel oral anticoagulants (NOACs) as primary prophylaxis remains limited. Methods: In this retrospective, single-center study, we analyzed 101 MM patients treated with IMiD-based therapy between January 2020 and December 2024. All patients received NOAC prophylaxis (apixaban 2.5 mg twice daily or rivaroxaban 10\u201320 mg once daily), irrespective of baseline thrombotic risk. Clinical characteristics, comorbidities, and treatment details were collected. The primary outcome was objectively confirmed VTE, while secondary outcomes included bleeding events and treatment feasibility, assessed by treatment continuation without clinically significant bleeding. Results: Median age was 63 years (range 35\u201389); 36.6% were female. Lenalidomide and pomalidomide were used in 86.1% and 13.9%, respectively. Twenty-eight patients (27.7%) had relapsed\/refractory disease, while 72.3% were newly diagnosed. Over a median NOAC exposure of 6 months, two patients (2.0%) developed VTE (both deep vein thrombosis). One major bleeding event (1.0%) occurred. Conclusions: Universal NOAC prophylaxis in MM patients receiving IMiD-based therapy was associated with a low incidence of thromboembolic events and an acceptable safety profile. These real-world findings suggest that NOACs may represent a practical and effective alternative to aspirin or LMWH, potentially overcoming the limitations of score-based prophylaxis strategies.<\/jats:p>","DOI":"10.3390\/jcm15020453","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:34:12Z","timestamp":1767778452000},"page":"453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience"],"prefix":"10.3390","volume":"15","author":[{"given":"Yasa Gul","family":"Mutlu","sequence":"first","affiliation":[{"name":"Department of Hematology, Gaziantep City Hospital, Gaziantep 27470, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrar","family":"Uzunabdullah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9772-3584","authenticated-orcid":false,"given":"Duha","family":"Yahya","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3033-7542","authenticated-orcid":false,"given":"Hasan Basri","family":"Erg\u00fcn","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fcreyya","family":"Yi\u011fit Kaya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senem","family":"Maral","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin Saffet","family":"Bek\u00f6z","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylag\u00fcl","family":"Kaynar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istanbul Medipol University, Istanbul 34214, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-4113","authenticated-orcid":false,"given":"\u00d6m\u00fcr G\u00f6kmen","family":"Sevindik","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istanbul Florence Nightingale Hospital, Istanbul 34381, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fotiou, D., Gavriatopoulou, M., and Terpos, E. (2020). Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers, 12.","DOI":"10.3390\/cancers12010191"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MBC.0000000000000296","article-title":"Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma","volume":"26","author":"Huang","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","article-title":"Hyperviscosity in plasma cell dyscrasias","volume":"55","author":"Kwaan","year":"2013","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/CCO.0b013e3283592331","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"24","author":"Falanga","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s00277-024-05733-9","article-title":"Thromboprophylaxis in multiple myeloma: A case-based review with practical guidelines","volume":"103","author":"Charalampous","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.18630","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","volume":"201","author":"Dima","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: Development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: Derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11239-017-1534-9","article-title":"Use of direct oral anticoagulants in patients on immunomodulatory agents","volume":"44","author":"Man","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cornell, R.F., Goldhaber, S.Z., Engelhardt, B.G., Moslehi, J., Jagasia, M., Patton, D., Harrell, S., Hall, R., Wyatt, H., and Piazza, G. (2019). Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00045"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma\u2014Choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_14","first-page":"CD014739","article-title":"Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents","volume":"9","author":"Kahale","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2022.03.001","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study","volume":"213","author":"Sayar","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102865","DOI":"10.1016\/j.rpth.2025.102865","article-title":"A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma","volume":"9","author":"Codreanu","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:48:12Z","timestamp":1767779292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020453"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020453","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}